2023年12月最新中科院分区表数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Expert Review of Anticancer Therapy EXPERT REV ANTICANC （此期刊被最新的JCR期刊SCIE收录） LetPub评分 6.3
51人评分
我要评分
声誉 7.6 影响力 5.1 速度 7.1 | |||||||||||||||||||||
| 期刊ISSN | 1473-7140 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1744-8328 | |||||||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 3.3 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2024年3月26日：2.849 | |||||||||||||||||||||
| 2022-2023自引率 | 3.00%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 4.2 | |||||||||||||||||||||
| h-index | 59 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.tandfonline.com/toc/iery20/current#.V48dKEz9cSQ | |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/ert | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Expert Review of Anticancer Therapy的语言要求，还能让Expert Review of Anticancer Therapy编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Expert Review of Anticancer Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | EXPERT REVIEWS, UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB | |||||||||||||||||||||
| 出版商 | Taylor and Francis Ltd. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Bimonthly | |||||||||||||||||||||
| 出版年份 | 2001 | |||||||||||||||||||||
| 年文章数 | 106点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 9.17% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 34.91% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：3区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1473-7140%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 偏慢,4-8周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 容易 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Expert Review of Anticancer Therapy顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Effect of primary tumor resection on survival in patients with asymptomatic unresectable metastatic colorectal cancer: a systematic review and meta-analysis Author: Zhang, Chengren; Cao, Cong; Liu, Lili; Lv, Yaochun; Li, Jingjing; Lu, Jiyong; Wang, Shuai; Du, Binbin; Yang, Xiongfei Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. 23, Issue 1, pp. 107-115. DOI: 10.1080/14737140.2023.2149497 PubMed DOI |
| 2. | Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer Author: Yang, James Chih-Hsin; Zhou, Caicun; Janne, Pasi A.; Ramalingam, Suresh S.; Kim, Tae Min; Riely, Gregory J.; Spira, Alexander, I; Piotrowska, Zofia; Mekhail, Tarek; Campelo, Maria Rosario Garcia; Felip, Enriqueta; Bazhenova, Lyudmila; Jin, Shu; Kaur, Manmit; Diderichsen, Paul M.; Gupta, Neeraj; Bunn, Veronica; Lin, Jianchang; Churchill, Eric; Mehta, Minal; Nguyen, Danny Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. 23, Issue 1, pp. 95-106. DOI: 10.1080/14737140.2023.2157815 PubMed DOI |
| 3. | Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials Author: Zou, Yihua; Si, Yue; Tong, Fangqin; Guan, Meng; Bi, Chun; Wang, Xia Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. 23, Issue 2, pp. 217-227. DOI: 10.1080/14737140.2023.2157816 PubMed DOI |
| 4. | Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis Author: Li, Jiajia; Xu, Yubo; Zhang, Jie; Wang, Shaohai; Wang, Xiaoyu; Guo, Huayan; Miao, Guojun Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. 23, Issue 3, pp. 339-345. DOI: 10.1080/14737140.2023.2168648 PubMed DOI |
| 5. | Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance Author: Ding, Jianghua; Ding, Xinjing; Leng, Zhaohui Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. 23, Issue 2, pp. 187-198. DOI: 10.1080/14737140.2023.2170879 PubMed DOI |
| 6. | Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis Author: Zhang, Wenjian; Zhou, Lushan; Di, Jianzhong Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. 23, Issue 2, pp. 207-216. DOI: 10.1080/14737140.2023.2168647 PubMed DOI |
| 7. | Association between CD8+tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis Author: Zheng, Qi-Ming; Li, Yuan-Yuan; Wang, Ye-Peng; Li, Guo-Xiang; Zhao, Meng-Meng; Sun, Zhi-Gang Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2023.2208351 PubMed DOI |
| 8. | Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis Author: Li, Jinghui; Ma, Yongli; Wen, Liang; Zhang, Guosheng; Yao, Xueqing Journal: EXPERT REVIEW OF ANTICANCER THERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14737140.2023.2181796 PubMed DOI |
| 9. | L1 cell adhesion molecule as a therapeutic target in cancer. Author: Yu X, Yang F, Fu DL, Jin C. Journal: Expert Rev Anticancer Ther. 2016;16(3):359-71. doi: 10.1586/14737140.2016.1143363. Epub 2016 Feb 6. PubMed |
| 10. | Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Author: Chen H, Wang S, Zhang H, Nice EC, Huang C. Journal: Expert Rev Anticancer Ther. 2016 Jul 5:1-12. [Epub ahead of print] PubMed |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共13条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
